68Ga-FAPI PET/CT in Challenging Thyroid Cancer Cases: Complementary Findings and Interpretive Pitfalls in a Seven-Patient Case Series
Year: 2026
Type: article
Study design: Case Report
Abstract: Gallium-68 fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT targets cancer-associated fibroblasts and may provide complementary information in challenging thyroid cancer cases. We retrospectively evaluated seven patients with thyroid cancer who underwent 68Ga-FAPI-04 PET/CT between November 2023 and December 2025 for suspected recurrent or metastatic disease or further characterization of known disease. The cohort comprised three males and four females (median age, 39 years; range, 20–81 years) with follicular cell-derived or medullary thyroid carcinoma. Findings were compared descriptively with available anatomical imaging, radioiodine scintigraphy, 18F-FDG PET/CT, and 68Ga-DOTATATE PET/CT. Histopathology and clinical or imaging follow-up were used for lesion characterization where available. FAPI uptake varied substantially, ranging from low uptake in histologically confirmed metastatic follicular thyroid carcinoma (SUVmax 1.5) to intense uptake in a gluteal lesion (early/delayed SUVmax 17.7/32.6) that subsequently regressed metabolically, favoring an inflammatory process. FAPI provided additional lesion characterization in medullary thyroid carcinoma, although a newly identified parapharyngeal lesion remained unconfirmed, and the muscular focus was indeterminate. Discordance with FDG and DOTATATE findings was also observed. 68Ga-FAPI PET/CT may provide complementary information in selected thyroid cancer cases but requires cautious interpretation alongside other imaging, histopathology, and follow-up.
Institutions: King Hussein Cancer Center, University of Jordan
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7237229571
